Thallion Pharmaceuticals Inc.

Thallion Pharmaceuticals Inc.

April 13, 2007 08:00 ET

Thallion Pharmaceuticals Inc. Announces Update of Recent FDA Advisory Committee Meeting

MONTREAL, QUEBEC--(CCNMatthews - April 13, 2007) - Thallion Pharmaceuticals Inc. (TSX:TLN) today provided an update on its participation in a joint advisory panel convened by the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research. Thallion, as a sponsor participant, presented to the joint committee on questions posed by the FDA, on subjects including the suitable endpoints for products seeking approval for the treatment of Shiga Toxin-producing Escherichia coli infection (STEC). The joint committee considered, among several issues related to therapeutic development in STEC, alternatives to standard endpoints historically used, including those proposed by Thallion to the FDA.

The key question before the panel relevant to Thallion was the appropriate primary endpoint for the determination of efficacy in a pivotal trial. To date, Hemolitic Uremic Syndrome (HUS) has been the primary efficacy endpoint for all recent clinical trials for STEC. The panel discussed the relative merits of potential alternative endpoints, including composites of surrogate endpoints such as those proposed by Thallion.

"Given that no trial for this indication has ever used a primary efficacy endpoint outside of HUS we are encouraged by the outcome of the meeting," said Lloyd M. Segal, President and Chief Executive Officer of Thallion Pharmaceuticals Inc. "Our next step is to pursue further discussions with the FDA on the use of composite endpoints prior to initiating our trial."

The joint committee was convened by the FDA to discuss clinical development paths and trial designs for products seeking approval for prevention of sequela of Shigma Toxin-producing Escherichia coli infection. The committee was comprised of members from the Anti-Infective Drugs Advisory Committee and the Pediatric Advisory Committee of the Center for Drug Evaluation and Research (CDER).

About STEC

STEC infections affect an estimated 314,000 people annually in Industrialized Countries, including approximately 110,000 people in the U.S. and 97,000 people in the EU according to the Centers for Diseases Control and Prevention and the European Medicines Agency, respectively. In 50% of people that experience Shigatoxin mediated events, clinical outcomes include hemorrhagic colitis, hemolytic anemia, thrombocytopenia, kidney failure, brain damage, HUS and, for 3% to 5% of the latter patients, death. STEC is the principal cause of HUS, a life threatening condition that appears more frequently in infected children and is the most common cause of acute renal failure in these patients. There is no approved treatment for STEC infections, and antibiotics have been shown to increase the risk and severity of Shigatoxin-mediated events.

About Thallion Pharmaceuticals Inc.

Pursuant to the March 14, 2007 amalgamation between Ecopia and Caprion, Thallion's shares are listed on the Toronto Stock Exchange under the ticker symbol: TLN. Additional information about the Company can be obtained from Thallion's website at

About Caprion

Caprion Pharmaceuticals Inc. is a clinical-stage biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology. Caprion's clinical stage programs include Shigamabs®, a product for the treatment of Shigatoxin-producing E. coli bacterial infections, and CAP-232, a targeted therapy with potential efficacy in multiple oncology indications. CellCarta®, Caprion's proprietary proteomics technology, provides Caprion with an effective means to identify novel drug targets, predict which therapeutics may be safer and more efficacious, and identify which patients may benefit most from a particular therapy.

About Ecopia

Ecopia is finding novel anticancer therapies from microorganisms, one of the most prolific sources of drugs. The Company's lead compound, ECO-4601 is a novel small molecule with a dual mechanism of action currently in Phase I clinical development. Like well known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from a nonpathogenic microorganism. However, unlike these drugs that were discovered decades ago, ECO-4601 is the fruit of a unique drug discovery platform called the DECIPHER® technology and represents a new chemical class, from which many analogs are being synthesized.

Forward-Looking Statements

Certain statements in this press release that do not relate exclusively to historical facts are forward-looking statements. These statements relate to future events or the Corporation's future performance. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential", "targeting", "intend", "could", "might", "continue", or the negative of these terms or other comparable terminology. These statements are only predictions. In addition, this press release may contain forward-looking statements attributed to third party industry sources.

Undue reliance should not be placed on these forward-looking statements, as there can be no assurance that the plans, intentionsor expectations upon which they are based will occur. By its nature, forward-looking information involves numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur and may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Forward-looking statements in this press release speak only as of the date of this press release and include, but are not limited to, statements with respect to (i) the potential combination of Ecopia and Caprion, (ii) the potential private placement of securities of the amalgamated company, (iii) the ability to raise future capital to fund the Corporation's research and development activities; (iv) success and timely completion of clinical studies; (v) the pursuit of clinical trials in the United States; (vi) the potential of ECO-4601 as a chemotherapy against primary brain cancer; (vii) the potential of ECO-4601 in the treatment of breast, prostate, colon, lung and ovarian cancers; (viii) the identification of a second generation ECO-4601 compound; (ix) the identification of a non-ECO-4601 related compound as a candidate for another regulatory filing;
(x) the grant by the United States Patent and trademark Office of a patent directed to ECO-4601 based on the Corporation's notice of allowance; and (xi) the earning of revenues from the exercise of exclusivity options on out-licensed patent properties may rely on a number of assumptions concerning future events and are therefore subject to a number of risks and uncertainties, many of which are outside Ecopia's control. Actual results may therefore vary materially from the expectations expressed by the Corporation and depend on a number of factors. These factors include, but are not limited to: (i) the possibility of not satisfying all closing conditions to complete the combination of Ecopia and Caprion, (ii) the ability of Ecopia of raising sufficient capital for purposes of the proposed private placement, (iii) risks related to the integration of acquisitions, (iv) the possibility of delays in approval of patients in Phase I trial; (v) scientific uncertainties relating to the correlation between preclinical animal data and human clinical data; (vi) the safety and efficacy of ECO-4601 as a cancer treatment; (vii) timely progress and completion of Phase I study; (viii) withdrawal of a notice of allowance by the United States Patent and Trademark Office; (ix) uncertainties related to the regulatory process for drug development; (x) the ability for the Corporation to fund its future operations in light of the lack of operating revenues for the years to come;(xi) and the impact of general economic conditions. A more complete discussion of the risks and uncertainties facing the Corporation appears in Ecopia's 2006 Management's Discussion and Analysis of Financial Position and Results of Operations for fiscal 2006 and in its 2006 Annual Information Form available at Except as required by law, Ecopia does not undertake and disclaims any obligation to update or revise its forward-looking statements or forward-looking information whether as a result of new information, future events, or otherwise.

Contact Information